Navigation Links
Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Date:2/15/2008

tere(R) (docetaxel) chemotherapy plus prednisone in HRPC patients with metastatic disease who are asymptomatic with respect to cancer-related pain. The primary endpoint of the trial is an improvement in survival. An interim analysis of the trial was recently conducted by an independent data monitoring committee in the timeframe originally estimated and resulted in the recommendation to continue the trial. The company expects to have enough events to trigger the final analysis of VITAL-1 in the second half of 2009. VITAL-2, which the company expects to fully enroll with approximately 600 patients in the first half of 2009, is designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. The company expects to have enough events to trigger an interim analysis of VITAL-2 in the first half of 2009.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational products comprised of whole tumor cells that have been modified to secrete GM- CSF (granulocyte-macrophagecolony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety. GVAX is administered via intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GVAX immunotherapy for prostate cancer in its bioreactor-based manufacturing plant in Hayward, California, a facility that is also capable of manufacturing the product for commercialization.

About Cell Genesys

Cell Genesys is focused on the development and comme
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
2. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
7. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Second Thoughts about Fluoride, Reports Scientific American
11. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... DUBLIN , Aug. 31, 2015 ... the addition of the "Introduction to Veterinary ... to their offering. This course ... a good introduction to those concerned with Veterinary ... experienced personnel who reqire a better understanding of ...
(Date:9/1/2015)... Egalet Corporation (Nasdaq: EGLT ) ... on discovering, developing, and commercializing innovative pain treatments, ... data on SPRIX ® (ketorolac tromethamine) Nasal ... candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone ... to be held September 8 to 12 in ...
(Date:9/1/2015)... , Sept. 1, 2015  Based on ... management market, Frost & Sullivan recognizes Pie ... Frost & Sullivan Award for Technology Leadership. ... has designed innovative and easy-to-use imaging solutions—its ... and reproducible quantitative results for cardiovascular diagnosis ...
Breaking Medicine Technology:Introduction to Veterinary Pharmacovigilance Seminar (London, UK - September 23-24) 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 2Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 3Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 4Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 5
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
... Pharmaceuticals, Inc. (Nasdaq: AVNR ) today announced that company ... in March. Citi 2011 Global Healthcare Conference ... Tuesday March 1, 2011 Presentation time: 8:00am ET ... Location: Boston Marriott, Boston, MA Presentation date: Tuesday March ...
Cached Medicine Technology:Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , the ... muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events this ... raise awareness of the FSH Society and further FSHD research. , The ...
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO is pleased to announce ... Connectivity Kit, EasySampler data is automatically transferred to, and reported with, the referring ... platform. , EasySampler fully automates the sampling process including sampling capture, ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 West ... career opportunities will be attending from across the country. All specialties will be ...
(Date:9/1/2015)... ... ... Dr. Trace Curry successfully placed one of the first ORBERA™ Intra-gastric Balloons ... FDA has approved two intra-gastric balloons, the ORBERA ™ Managed Weight Loss System ... weight loss procedures available to Americans. , Dr. Curry, medical director at ...
(Date:9/1/2015)... ... 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides an ... in the hands, delivering smooth, natural-looking results that can last up to one year ...
Breaking Medicine News(10 mins):Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3
... (HealthDay News) -- Long-term survival rates are low for intensive ... arrest, a new study finds. Canadian researchers looked at ... arrest while in the ICUs of four Alberta hospitals. Of ... for one year, and 16 percent for five years. ...
... that an infant with an older sibling with autism also ... 10 percent, is substantially higher at approximately 19 percent, a ... Davis MIND Institute has found. While the study found a ... found an even more elevated risk of recurrence of over ...
... seemingly approaching a day when they will be able to ... cells. You need nerves or pancreas, bone or skin? With ... laboratory tissue culture dish promises to yield therapeutic wonders. But ... potential problem: Any remaining embryonic stem cells - those that ...
... Standing water is a breeding ground for mosquitoes that can ... many urban families don,t take simple steps such as dumping ... Last summer, researchers polled 242 urban residents to find out ... risks posed by standing water, a mosquito breeding ground. Researchers ...
... , FRIDAY, Aug. 12 (HealthDay News) -- The ... U.S. Treasury Department today awarded $185 million to 13 states ... Affordable Insurance Exchanges -- a cornerstone of President Obama,s health ... proposed three rules for administering the plan, which will include ...
... 12 (HealthDay News) -- Patients who take antipsychotic ... complications, researchers have found. Known as "metabolic ... antipsychotic drugs. For example, up to 60 percent ... cholesterol, 40 percent have high blood pressure and ...
Cached Medicine News:Health News:Recurrence risk of autism in younger siblings higher than thought 2Health News:Recurrence risk of autism in younger siblings higher than thought 3Health News:Stanford discovery may eliminate potentially lethal side effect of stem cell therapy 2Health News:Stanford discovery may eliminate potentially lethal side effect of stem cell therapy 3Health News:Stanford discovery may eliminate potentially lethal side effect of stem cell therapy 4Health News:Get Rid of Standing Water to Protect From Mosquitoes 2Health News:Feds Outline Rules for States' Insurance Exchanges 2Health News:Patients Taking Antipsychotics Urged to Get Routine Physicals 2
... quick and easy automated refill system ... space on your laboratory bench and ... easy-to-use, one-hand system, you only need ... of Diamond Tips. All sizes of ...
... TowerPack is an innovative, quick ... Diamond Tips. Use 60% less space ... less plastic. With this amazingly easy-to-use, ... box for the whole range of ...
10 L, Racked, 96 tips/rack Extended length pipette tips recommended for 5 and 10 L pipettes....
This pipette tip facilitates the loading of samples onto polyacrylamide gels for DNA sequencing. The Geloader Tip has a 15 mm capillary with a defined diameter of less than 0.3 mm. The flexibility of...
Medicine Products: